Clinical trial researching therapy for aggressive blood cancers

Doctor speaking with patient

Credit: Canva

Non-Hodgkin lymphomas are aggressive blood cancers that can be difficult to treat and may return after treatment. Examples include diffuse large B-cell lymphoma and peripheral T-cell lymphoma. A clinical trial led by Christopher J. Melani, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is researching a combination drug therapy for the diseases. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.

For more information, please contact the NCI Medical Oncology Referral Office at (240) 760-6050 or identifier: NCT05371054

NCI Protocol ID: 000633

Official Title: Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Posted on Thu, 05/18/2023